Company profile: Evaxion Biotech
1.1 - Company Overview
Company description
- Provider of AI-immunology™ platform-driven immunotherapies for cancer and infectious diseases, including EVX-01, a Phase 2 personalized cancer vaccine targeting patient-specific tumor antigens, and EVX-B1, a vaccine antigen against Staphylococcus Aureus, plus models PIONEER™, ObsERV™, and AI-DEEP™ for vaccine design and CPI response prediction.
Products and services
- AI-Immunology™: A proprietary platform decoding the human immune system with artificial intelligence to discover and develop novel immunotherapies for cancer and infectious diseases, enabling a pipeline of novel product candidates
- EVX-01: A personalized cancer vaccine in Phase 2 clinical trial, targeting patient-specific tumor antigens unique to each patient’s cancer
- AI-DEEP™: A predictive model utilizing artificial intelligence to predict patient responses to cancer CPI immunotherapy, estimating responses to checkpoint inhibitor therapy in oncology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Evaxion Biotech
Vaxcyte
HQ: United States
Website
- Description: Provider of vaccines and vaccine development technologies, including VAX-24, a 24-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease in adults (FDA Breakthrough Therapy); VAX-31, a 31-valent pneumococcal conjugate candidate; the XpressCF cell-free platform for site-specific conjugation to enhance immunogenicity; and preclinical programs for Group A Strep, periodontitis, and Shigella.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxcyte company profile →
AdvanDx
HQ: United States
Website
- Description: Provider of rapid and accurate molecular in vitro diagnostic tests and kits for identifying pathogens causing critical infections in hospitalized patients, enabling healthcare providers to optimize antibiotic therapy earlier to improve patient outcomes while limiting unnecessary antibiotic use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AdvanDx company profile →
Visby Medical
HQ: United States
Website
- Description: Provider of instrument-free PCR diagnostic tests for infectious disease detection, including the single-use Sexual Health Test that detects Chlamydia, Gonorrhea, and Trichomoniasis from self-collected vaginal swabs in under 30 minutes, and the Respiratory Health Test that detects and differentiates COVID-19, Influenza A, and Influenza B via nasopharyngeal swabs in under 30 minutes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Visby Medical company profile →
Artus Biotech
HQ: Germany
Website
- Description: Provider of DNA-based diagnostic kits focused on PCR and real-time PCR, developed, produced, and sold for detection of infectious agents and use in pharmacogenomics and veterinary applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artus Biotech company profile →
Iomai
HQ: United States
Website
- Description: Provider of vaccines and immune system stimulants delivered via transcutaneous immunization (TCI), a novel needle-free technology that taps antigen-presenting cells in the outer layers of the skin to generate an enhanced immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iomai company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Evaxion Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Evaxion Biotech
2.2 - Growth funds investing in similar companies to Evaxion Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Evaxion Biotech
4.2 - Public trading comparable groups for Evaxion Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →